Page last updated: 2024-08-25

ailanthone and mdv 3100

ailanthone has been researched along with mdv 3100 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, A; Chen, H; Cong, X; Gao, S; He, Y; Hu, M; Liu, M; Peng, S; Qin, M; Wang, J; Wang, L; Wang, X; Wu, H; Yi, Z1
Liu, M; Peng, S; Yi, Z1

Other Studies

2 other study(ies) available for ailanthone and mdv 3100

ArticleYear
Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer.
    Nature communications, 2016, 12-13, Volume: 7

    Topics: Alternative Splicing; Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Models, Molecular; Molecular Chaperones; Molecular Targeted Therapy; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Phosphoproteins; Prostaglandin-E Synthases; Prostatic Neoplasms, Castration-Resistant; Protein Stability; Proteolysis; Quassins; Receptors, Androgen; Xenograft Model Antitumor Assays

2016
Ailanthone: a new potential drug for castration-resistant prostate cancer.
    Chinese journal of cancer, 2017, 03-03, Volume: 36, Issue:1

    Topics: Benzamides; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quassins

2017